Lowering serum uric acid levels: What is the optimal target for improving clinical outcomes in gout?

Arthritis Care and Research

Volumn 57, Issue 7, 2007, Pages 1324-1328

  Perez Ruiz, Fernando ^a   Lioté, Frédéric ^b,c  

^a HOSPITAL DE CRUCES   (Spain)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

GOUT; HUMAN; OUTCOMES RESEARCH; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; URIC ACID BLOOD LEVEL;

ALLOPURINOL; GOUT; HUMANS; TREATMENT OUTCOME; URIC ACID;

EID: 34250724118     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23007     Document Type: Review

References (37)

1. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Practical rheumatology. 3rd ed. Philadelphia: Mosby; 2004.
2. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995;48:1153-8.
3. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
4. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-98.
5. Arromdee E, Michet CJ, Crowson CS, O'Fallon M, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403-6.
6. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis 1997;56:22-6.
7. Brill JM, McCarty DJ. "Studies on the nature of gouty tophi" by Max Freudweiler, 1899. An inflammatory response to injected sodium urate, 1899: an abridged translation, with comments. Ann Intern Med 1964;60:486-505.
8. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6.
9. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000;27:1045-50.
10. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000;27:1501-5.
11. Seegmiller JE. The acute attack of gouty arthritis. Arthritis Rheum 1965;8:714-25.
12. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972;15:189-92.
13. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis Rheum 1991;34:141-5.
14. Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med 1999;131:756-9.
15. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout: can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80.
16. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5.
17. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966;64:229-58.
18. Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. N Z Med J 2005;118:37-42.
19. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55.
20. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with
21. allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
22. Darmawan J, Rasker JJ, Nuralim H. The effect of control and self-medication of chronic gout in a developing country: outcome after 10 years. J Rheumatol 2003;30:2437-43.
23. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, muiticenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23.
24. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32.
25. Yue TF, Gutman AB. Effect of allopurinol (4-hyroxypyrazolo-(3,4-d) pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964;37:885-98.
26. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998;431:13-8.
27. Nakayama DA, Barthelemy C, Carrera G, Lightfoot RW Jr, Wortmann RL, Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984;27:468-71.
28. Vazquez-Mellado J, Cuan A, Magana M, Pineda C, Cazarin J, Pacheco-Tena C, et al. Intradermal tophi in gout: a case-control study. J Rheumatol 1999;26:136-40.
29. Goldfarb E, Smyth CJ. Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis Rheum 1966;9:414-23.
30. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
31. Perez-Ruiz F, Calabozo M, Herrero-Beites AM, Garcia-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000;86:287-91.
32. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-5.
33. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II. Management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
34. McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991;34:1489-94.
35. Simkin PA. Management of gout. Ann Intern Med 1979;90:812-6.
36. Schumacher HR. Crystal-induced arthritis: an overview. Am J Med 1996;100:46S-52S.
37. Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein AC, Gunter MJ, et al. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother 2006;40:386-91.